NECTA Annual Drug Development Meeting – Lyssna här

Avsnitt

Precision Medicine - Have we reached a therapeutic plateau? 2024 and Beyond….
9 apr· NECTA Annual Drug Development Meeting
Speakers: Prof Anthony Joshua & Dr Rasha Cosman,
St Vincent’s Hospital Sydney
Session 3, Talk 3
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare
Dose Ranging and Optimisation in Oncology: Implications for the Design and Conduct of Early Clinical Trials
8 apr· NECTA Annual Drug Development Meeting
Speaker: Prof Lesley Seymour, Queens University Kingston Ontario - Session 3, Talk 2
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare
Saknas det avsnitt?

Klicka här för att uppdatera flödet manuellt.
Artificial Intelligence (AI) and Big Data in clinical trials
8 apr· NECTA Annual Drug Development Meeting
Speaker: Dr Raanan Berger, Sheba Medical Center Hospital
Session 3, Talk 1
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare
Myeloid cell headwinds for GD2-CAR-T cell therapy
8 apr· NECTA Annual Drug Development Meeting
Speaker: Prof Michael Brown, Royal Adelaide HospitalSession 2, Talk 2
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare
Developing tumour microenvironment CARs
8 apr· NECTA Annual Drug Development Meeting
Speaker: Prof Paul Neeson, Peter MacCallum Cancer Centre - Session 2, Talk 1
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare
Findings from Australian oncology early career professionals
8 apr· NECTA Annual Drug Development Meeting
Dr Jenny Liu, St Vincent’s Hospital Sydney - Benefitsof liquid biopsy with an early phase trial referral networkDrAbhijit Pal, Liverpool Hospital - Informedconsent for early phase cancer clinical trials – common pitfalls and pragmatic solutionsDr Christina Teng, Scientia Clinical Research - Case Study: the impact of trial participation on the individual patientSession 1, Section 2
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare
Multiphase Clinical Trials Development and Novel Designs
8 apr· NECTA Annual Drug Development Meeting
Speaker: Prof Igor Puzanov, Roswell Park Medical CentreSession 1, Talk 1
- Lyssna Lyssna igen Fortsätt Lyssnar...
- Lyssna senare Lyssna senare

Avsnitt

Precision Medicine - Have we reached a therapeutic plateau? 2024 and Beyond….

Dose Ranging and Optimisation in Oncology: Implications for the Design and Conduct of Early Clinical Trials

Artificial Intelligence (AI) and Big Data in clinical trials

Myeloid cell headwinds for GD2-CAR-T cell therapy

Developing tumour microenvironment CARs

Findings from Australian oncology early career professionals

Multiphase Clinical Trials Development and Novel Designs